Skip to main content

Table 5 Correlation between alterations in TP53/CHEK2/ATM ("hit") and in vivo resistance to epirubicin

From: Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

 

Hit

Non-Hit

Progressive disease

71

32

Responders

253

724

  

P = 0.0074

  1. Cohort 2 (Epirubicin)
  2. 1 Patients lacking response to therapy/with mutations in TP53 (L2/L3) or CHEK2 or low expression of ATM (lower 20% percentile of cohort)
  3. 2 Patients lacking response to therapy/without mutations in TP53 (L2/L3) or CHEK2 low expression of ATM (lower 20% percentile of cohort)
  4. 3 Patients with response to therapy (SD, PR or CR)/with mutations in TP53 (L2/L3) or CHEK2 or low expression of ATM (lower 20% percentile of cohort)
  5. 4 Patients with response to therapy (SD, PR or CR)/without mutations in TP53 (L2/L3) or CHEK2 or low expression of ATM (lower 20% percentile of cohort)
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us